Literature DB >> 18856159

Dissecting cellulitis of the scalp treated with rifampicin and isotretinoin: case reports.

Sofia Georgala1, Chrysovalantis Korfitis, Dikaia Ioannidou, Theodosis Alestas, Georgios Kylafis, Caterina Georgala.   

Abstract

Dissecting cellulitis of the scalp, or perifolliculitis capitis abscedens et suffodiens, is an uncommon chronic suppurative disease of the scalp manifested by follicular and perifollicular inflammatory nodules that suppurate and undermine, forming intercommunicating sinuses, and leading to scarring alopecia. Treatment generally fails to obtain a permanently successful result; thus, many therapeutic options have been proposed. We report 4 cases of dissecting cellulitis of the scalp successfully treated with oral rifampicin and oral isotretinoin. To our knowledge, this is the first report of oral rifampicin used concomitantly with oral isotretinoin in this disease entity. We also present a brief review of the literature on the topic.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18856159

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  4 in total

Review 1.  Updated Physician's Guide to the Off-label Uses of Oral Isotretinoin.

Authors:  Steven Brandon Nickle; Nathan Peterson; Michael Peterson
Journal:  J Clin Aesthet Dermatol       Date:  2014-04

2.  Dissecting Cellulitis of the Scalp Responding to Intravenous Tumor Necrosis Factor-alpha Antagonist.

Authors:  Uwe Wollina; Astrid Gemmeke; André Koch
Journal:  J Clin Aesthet Dermatol       Date:  2012-04

3.  Folliculitis et perifolliculitis capitis abscedens et suffodiens controlled with a combination therapy: systemic antibiosis (metronidazole plus clindamycin), dermatosurgical approach, and high-dose isotretinoin.

Authors:  Georgi Tchernev
Journal:  Indian J Dermatol       Date:  2011-05       Impact factor: 1.494

4.  Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions.

Authors:  Sherman Chu; Lauren Michelle; Chloe Ekelem; Calvin T Sung; Nathan Rojek; Natasha A Mesinkovska
Journal:  Arch Dermatol Res       Date:  2020-11-05       Impact factor: 3.017

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.